Solve Therapeutics vs Biconomy
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxicity. Two Phase 1b solid tumor trials active.
About
Solve Therapeutics develops antibody-drug conjugates (ADCs) using its proprietary CloakLink technology — which reduces the hydrophobicity and systemic toxicity that are the two primary causes of ADC clinical failure. The company raised $120 million in an oversubscribed financing round in November 2025, with Merck & Co. making a direct equity investment (rather than a typical licensing deal), bringing total funding to $321 million. Two ADC programs (SLV-154 and SLV-324) are in active Phase 1b trials in solid tumor patients.
Web3 authentication and account abstraction infrastructure enabling gasless transactions and simplified dApp onboarding; ERC-4337 implementation allows dApps to sponsor gas fees on behalf of users and accept ERC-20 token gas payment for mainstream-accessible wallet experiences.
About
Biconomy is a Web3 infrastructure platform focused on making decentralized applications usable by mainstream audiences who are not familiar with cryptocurrency gas mechanics. Its core product implements account abstraction via ERC-4337, allowing dApp developers to sponsor gas fees on behalf of users, accept gas payment in ERC-20 tokens instead of native currency, and batch multiple on-chain transactions into a single user action. These capabilities transform the user experience from one requiring native token balances and technical awareness into something closer to a conventional web application workflow.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.